StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Each factor shows RLYB's percentile within the scored universe — observational ranking, not a recommendation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $14.22 | $14.00 | -1.55% | 0.2M |
| 05-12 | $14.00 | $14.03 | +0.21% | 0.1M |
| 05-13 | $14.05 | $14.35 | +2.14% | 0.2M |
| 05-14 | $14.38 | $14.21 | -1.18% | 0.0M |
| 05-15 | $14.16 | $14.30 | +0.99% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for RLYB.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $212.00K | $858.00K | $636.00K | $424.00K |
Operating Income | $-8.73M | $-33.06M | $-26.65M | $-19.73M |
Net Income | $-8.28M | $-8.98M | $-3.13M | $-19.14M |
EPS (Diluted) | $-1.46 | $-1.59 | $-0.07 | $-0.43 |
Total Assets | $54.47M | $62.26M | $67.66M | $51.00M |
Total Liabilities | $4.20M | $4.30M | $4.63M | $5.04M |
Cash & Equivalents | $41.30M | $31.37M | $32.12M | $9.45M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 5.29M | 5.28M | 41.94M | 41.71M |
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Fundamentals not available for RLYB.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
RLYB is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.